{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:11:05Z","timestamp":1787019065880,"version":"build-2736575974"},"reference-count":21,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Michael Smith Health Professional Award"},{"DOI":"10.13039\/501100005614","name":"BC Cancer Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2026,2,19]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The long-acting somatostatin analogues (LA-SSAs) octreotide LAR (OCT) and lanreotide (LAN) improve progression-free survival (PFS) in gastrointestinal neuroendocrine tumors (NETs), however, no head-to-head comparison exists. We compared treatment patterns and efficacy in a small bowel and pancreatic NET population-based cohort from British Columbia, Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified 321 patients receiving either LAN or OCT for retrospective chart review. These somatostatin analogs were evaluated for impact on progression-free and overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Age, sex, ECOG, and primary site did not differ by treatment, however, LAN was more commonly used in higher grade tumors (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.019). PFS was longer for patients receiving LAN than OCT (Hazard Ratio (HR) 0.60, 95% CI 0.40-0.89,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.011). Similarly, overall survival (OS) was longer for patients receiving LAN than OCT (HR 0.45, 95% CI 0.28-0.73,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.016). Sensitivity analysis among patients diagnosed after both agents were reimbursed showed similar results for PFS (HR 0.50, 95% CI 0.28-0.90,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.018). There was similar dose escalation with LAN vs OCT (OR: 0.80, CI 0.38-1.77,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.70), with 29.4% of patients in the LAN group requiring LA-SSA dose escalation compared to 34.3% in the OCT group. There was numerically less short acting octreotide use in the LAN group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.087), with none of these patients requiring short acting octreotide, compared to 8.7% of the OCT group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>LAN was associated with longer time to cancer progression, as well as less use of short acting rescue octreotide in our population-based cohort. However, given the retrospective design and reimbursement-era differences, these findings should be interpreted cautiously and warrant confirmation in prospective or head-to-head studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10732748261417423","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:58:11Z","timestamp":1771520291000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Lanreotide and Octreotide LAR Use and Outcomes for Gastrointestinal Neuroendocrine Tumors in British Columbia, Canada"],"prefix":"10.1177","volume":"33","author":[{"given":"Ashley","family":"Paul","sequence":"first","affiliation":[{"name":"BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehara","family":"Mendis","sequence":"additional","affiliation":[{"name":"BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1541-7517","authenticated-orcid":false,"given":"Michael","family":"Diaz-Stewart","sequence":"additional","affiliation":[{"name":"University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Jao","sequence":"additional","affiliation":[{"name":"BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Boutin","sequence":"additional","affiliation":[{"name":"BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Safro","sequence":"additional","affiliation":[{"name":"BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Denault","sequence":"additional","affiliation":[{"name":"BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Speers","sequence":"additional","affiliation":[{"name":"BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Stuart","sequence":"additional","affiliation":[{"name":"Vancouver General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharlene","family":"Gill","sequence":"additional","affiliation":[{"name":"BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Renouf","sequence":"additional","affiliation":[{"name":"BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Schaeffer","sequence":"additional","affiliation":[{"name":"Vancouver General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Farnell","sequence":"additional","affiliation":[{"name":"Vancouver General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Loree","sequence":"additional","affiliation":[{"name":"BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3189-z"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4377"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000000818"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5057-3"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29099"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000080731"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-015-0492-7"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70410-2"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316158"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100510"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13264"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0589"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000519605"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000002100"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0368-0"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02060-1"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.4_suppl.608"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e318279d552"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0138"}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748261417423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748261417423","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748261417423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:24:22Z","timestamp":1777386262000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748261417423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":21,"alternative-id":["10.1177\/10732748261417423"],"URL":"https:\/\/doi.org\/10.1177\/10732748261417423","relation":{},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"article-number":"10732748261417423"}}